Across TCGA pan-cancer cohorts, KLHDC4 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of KLHDC4’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where KLHDC4 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types KLHDC4 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.
CCRCC, LUAD, and LSCC are the cancer types where KLHDC4 tumor–normal differential expression is most reproducible.